Compassionate Use Programme (CUP)
Access to Unapproved Medicines in Urgent
and Life-Threatening Situations
and Life-Threatening Situations
How it works
We work alongside manufacturers, treating physicians, and national regulators to ensure Compassionate Use is handled with sensitivity, precision, and full legal alignment.
Challenge:
When patients face serious or life-threatening conditions — and no approved treatment is available.
Solution
Compassionate Use Programmes may offer a path forward.
At COREX, we support ethical and compliant access to investigational or unlicensed medicines in cases where time is critical, and options are limited.
What Is Compassionate Use?
Compassionate Use (also known as Expanded Access in some regions) refers to the provision of a medicine that:
- Is still under development or awaiting approval
- Is not commercially available in the patient’s country
- May offer potential benefit where no alternatives exist
- Is requested for a specific group of patients or even one individual
These programmes are often authorised by national Ministries of Health or ethics committees, and require strict eligibility and documentation.
How COREX Supports Compassionate Use Supply
Importation & Customs Clearance of Unapproved Medicines
GxP-Compliant Storage & Temperature-Controlled Delivery
Documentation Handling & Regulatory Liaison
Support for Individual or Cohort-Based Access
Project Management Aligned With Ethics and Urgency
COREX Global Network
Ensuring seamless clinical supply solutions with local expertise and global reach.
Why choose COREX
for Compassionate Use?
Frequently Asked Questions
When is Compassionate Use appropriate?
Compassionate Use may provide a pathway to treatment when patients face serious or life-threatening conditions, no satisfactory treatment options are available, and access to an investigational or unapproved medicine is urgently needed.
How is Compassionate Use different from a Named Patient Programme?
Compassionate Use programmes may provide access to investigational or unapproved medicines for individual patients or patient groups under a structured regulatory framework. Named Patient Programmes are typically initiated by a physician for an individual patient and follow country-specific access provisions.
Can Compassionate Use provide access to investigational medicines?
Yes. In many countries, Compassionate Use programmes may allow access to investigational medicines before marketing authorisation, subject to local regulations, eligibility requirements, and regulatory approvals.
Who is eligible for Compassionate Use?
Compassionate Use is generally intended for patients with serious, life-threatening, or severely debilitating conditions who have no satisfactory treatment alternatives and cannot access an appropriate clinical trial. Eligibility requirements vary by country and programme.